EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study

Na Chen, Qiang Xu iD, Renting Song, Yesi Luo, Lingbo Xie, Jianying Zhou, Xiaojuan Wang

Infection and Drug Resistance · 2026-04 · Volume 19 · 1-11

DOI: 10.2147/idr.s582186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-04. Verfasst von Na Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the efficacy and safety of omadacycline (OMA) for the treatment of carbapenem-resistant organisms (CROs) infections, which are associated with substantial morbidity and mortality and limited therapeutic options.

Methods

The patients included were ≥18 years old, had CRO-positive cultures, and had been treated with OMA-based combination therapy for ≥72 hours. Common clinical comorbidities and markers of disease progression were collected. The primary outcome was 30-day all-cause mortality. The secondary outcomes included 30-day recurrence, resolution of signs and symptoms of infection, 90-day readmission, and OMA-possible adverse events.

Results

This study included 132 patients treated with OMA for CRO infections, with a median age of 67 years and a majority of male patients. Of the 132 patients analyzed, 78.8% were admitted to the intensive care unit, with hypertension, diabetes, and chronic pulmonary disease being the most frequent comorbidities. The median Charlson Comorbidity Index (CCI) score for the entire cohort was 5 (interquartile range [IQR], 4-7), indicating a moderate to high comorbidity burden. Pneumonia represented the predominant infection (84.8%). The overall 30-day mortality rate was 27.3%. In the Carbapenem-Resistant Acinetobacter baumannii (CRAB) cohort (n=89), OMA therapy was initiated promptly following culture confirmation, with a median treatment duration of 8 days. The 30-day mortality rate in this subgroup was 29.2% (26/89). Adverse events included elevated aspartate transaminase (21.3%, 19/89), alanine aminotransferase (18.0%, 16/89), alkaline phosphatase (23.6%, 21/89), blood urea nitrogen (25.8%, 23/89) and decreased fibrinogen levels (18.0%, 16/89). In the Carbapenem-Resistant Klebsiella pneumoniae (CRKP) cohort (n=57), the 30-day mortality rate was 29.8% (17/57), with a safety profile comparable to the CRAB group.

Conclusion

The results demonstrated that OMA has promising clinical efficacy against CRAB or CRKP infections in critically ill patients.

Schlagwörter

Stichwörter der Autor:innen

Carbapenem-resistant Acinetobacter baumanniicarbapenem-resistant Klebsiella pneumoniaeomadacyclinetetracycline

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
  • Pharmacy Department, People's Hospital of Haixizhou, Qinghai, People's Republic of China.
  • Pharmacy Department, People's Hospital of Changshan, Quzhou, People's Republic of China.
  • Department of Pharmacy, The Seventh Affiliated Hospital of Sun Yat-Sen University, Guangdong, People's Republic of China.
  • Department of Pharmacy, The First Division Hospital of Xinjiang Production and Construction Corps, Aksu, People's Republic of China.

ORCID-Profile: Qiang Xu

Zitieren

APA

Chen, N., Xu, Q., Song, R., Luo, Y., Xie, L., Zhou, J., & Wang, X. (2026). Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study. Infection and Drug Resistance, Volume 19, 1-11. https://doi.org/10.2147/idr.s582186

Vancouver

Chen N, Xu Q, Song R, Luo Y, Xie L, Zhou J, et al. Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study. Infection and Drug Resistance. 2026;Volume 19:1-11. doi:10.2147/idr.s582186

BibTeX
@article{Chen2026,
  author = {Chen, Na and Xu, Qiang and Song, Renting and Luo, Yesi and Xie, Lingbo and Zhou, Jianying and Wang, Xiaojuan},
  title = {Clinical Outcomes of Omadacycline in Critically Ill Patients Treated for Carbapenem-Resistant Organism Infections: A Retrospective Study},
  journal = {Infection and Drug Resistance},
  year = {2026},
  volume = {Volume 19},
  pages = {1--11},
  doi = {10.2147/idr.s582186}
}
Kostenlos starten →